Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ConvaTec ( (GB:CTEC) ) has issued an update.
Convatec has announced the exercise and grant of share options under its 2017 Save as You Earn scheme, involving key executives Jonny Mason and Karim Bitar. Jonny Mason, Interim CEO, exercised options for 10,346 shares, while CEO Karim Bitar was granted options for 10,253 shares. These transactions highlight Convatec’s commitment to aligning managerial interests with company performance, potentially impacting stakeholder confidence and market positioning.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
ConvaTec’s strong financial performance and strategic positioning are tempered by bearish technical indicators and a high valuation. Regulatory challenges may pose risks, but the company’s innovation pipeline and operational strength support a moderately positive outlook.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company that focuses on solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. The company operates in around 90 countries and is part of the FTSE 100 Index, with revenues exceeding $2 billion in 2024.
Average Trading Volume: 7,750,007
Technical Sentiment Signal: Hold
Current Market Cap: £4.86B
For an in-depth examination of CTEC stock, go to TipRanks’ Overview page.